The long awaited nesiritide trial was just published in NEJM. Not really all that new, as it had been presented in part at American Heart last November. The long and the short: no difference in the big outcomes, with a modest improvement in dyspnea at the price of more hypotension. If nesiritide has a niche I don't know what it is. It's certainly not a front line agent for acute decompensated heart failure in hospitalized patients.
HT to Hospital Medicine Quick Hits.